Back To Top
PRODUCTS  Inhibitors of Signal Transduction Pathways

Tip: To quickly find your search term on this page, press "Ctrl" + "f" on your keyboard (Command + "f" on a Mac) and use the find bar.
3-Deazaneplanocin A Catalog#: A-1417
         3-Deazaneplanocin A (DZNep) is an S-Adenosylhomocysteine Hydrolase inhibitor and histone methyltransferase EZH2 inhibitor. It switches on repressed tumor suppressor genes and induces apoptosis by inhibiting the expression of EZH2.
4SC-202 Catalog#: A-1971
         4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity.
5'-Deoxy-5-fluorouridine Catalog#: A-1915
A-1155463 Catalog#: A-6045
         A-1155463 is a selective inhibitor of BCL-XL
A-1210477 Catalog#: A-9036
         A-1210477 is a potent and selective MCL-1 inhibitor which binds to MCL-1 selectively and with sufficient affinity to disrupt MCL-1-BIM complexes in living cells.
A-1331852 Catalog#: A-6046
         A-1331852 is a selective inhibitor of BCL-XL.
ABBV-075 Catalog#: A-6007
         ABBV-075 is a potent BET inhibitor (bromodomain (BRD)-containing proteind) with potential antineoplastic activity.
ABC-1183 Catalog#: A-6049
         ABC-1183 is a is an inhibit for CDK9 and GSK3..
ABC294640 Catalog#: A-1269
         ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity.
ABL-001 Catalog#: A-1967
         An orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity.
ABT-199(GDC-0199) Catalog#: A-1231
         ABT-199 is a potent and selective inhibitor of BCL-2 in clinical trials.
ABT-263(Navitoclax) Catalog#: A-1001
         ABT-263 is a Bcl-2 family inhibitor, in clinical trials
ABT-492 Catalog#: A-1620
         ABT-492 CAS.189279-58-1
ABT-494 Catalog#: A-6104
         ABT-494 is a selective JAK1 inhibitor.
ABT-578 Catalog#: A-1618
         ABT-578 CAS.221877-54-9
ABT-737 Catalog#: A-1002
         ABT-737 is a Bcl-2 family inhibitor, pre-clinical
ABT-767 Catalog#: A-1244
         ABT-767 is a PARP in clinic trials.
ABT-806 Catalog#: A-1243
         ABT-806 is an EGFR inhibitor in clinic trials.
ABT-809 Catalog#: A-1389
         ABT-809 is an EGFR tyrosine kinase inhibitor.
ABT-888 (Veliparib)(Dihydrochloride salt) Catalog#: A-1910
         ABT-888 is a potent inhibitor of PARP-1 and PARP-2 (potency =5nM in vitro)
ABT-888 (Veliparib)(Free Base) Catalog#: A-1003
         ABT-888 is a potent inhibitor of PARP-1 and PARP-2 (potency =5nM in vitro)
AC-220 Catalog#: A-1518
         AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
AC-710 Catalog#: A-1972
         AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity.
ACP-196 (Acalabrutinib) Catalog#: A-1968
         ACP-196 (Acalabrutinib) is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
AEE-788 Catalog#: A-1105
         AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor
Afatinib (BIBW-2992) Catalog#: A-1122
         BIBW-2992 (Tovok) is an irreversible, potent, orally bioavailable inhibitor of EGFR and HER2 ...
Afatinib Dimaleate(BIBW-2992) Catalog#: A-1122S
AG-013736 (Axitinib) Catalog#: A-1156
         Axitinib (also known as AG-013736) is a small molecule tyrosine kinase inhibitor. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and cKIT (CD117).
AG-120 Catalog#: A-1323
         AG-120 is an IDH1 (isocitrate dehydrogenase) inhibitor.
AG-221 Catalog#: A-1324
         AG-221 is an IDH2 ( isocitrate dehydrogenase) inhibitor.
AG-348 Catalog#: A-1325
         AG-348 is a pyruvate kinase M2 (M2PK) inhibitor.
AG-881 Catalog#: A-6078
         AG-881 specifically inhibits mutant forms of IDH1 and IDH2.
AGI-6780 Catalog#: A-1328
         AGI-6780 is a potent and selective IDH2 inhibitor.
Altiratinib Catalog#: A-6038
         Altiratinib is an inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk)
AM-5992 Catalog#: A-1611
AMG-110 Catalog#: A-1600
AMG-176 Catalog#: A-6056
         AMG-176 is a selective MCL-1 inhibitor
AMG-208 Catalog#: A-1242
         AMG-208 is a potent c-Met inhibitor with an IC50 of 9.3 nM in clinical trials.
AMG-232 Catalog#: A-1354
         AMG-232 (AMG 232) is an extremely potent MDM2 inhibitor.
AMG-337 Catalog#: A-1601
         AMG 337 is an orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity.
AMG-47a Catalog#: A-1376
         AMG-47a is an orally bioavailable potent inhibitor of Lck and T cell proliferation.
AMG-51 Catalog#: A-6047
         AMG-51 is a selective c-Met inhibitor.
AMG-511 Catalog#: A-1352
         AMG-511 (AMG 511) is an orally bioavailable, highly potent and selective pan-PI3K inhibitor
AMG-900 Catalog#: A-1602
         AMG 900 is a small-molecule inhibitor of Aurora kinases A, B and C with potential antineoplastic activity.
AMG-925 Catalog#: A-1353
         AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor
Antroquinonol Catalog#: A-1379
         Antroquinonol is the pure compound extracted from Antrodia camphorata.
AP-23573 Catalog#: A-1004
         AP-23573 (MK-8669, Deforolimus) is an mTOR inhibitor
AP-24534 (Ponatinib) Catalog#: A-1158
         AP-24534 (Ponatinib), a novel inhibitor of BCR/ABL, FGFR, VEGFR.
AP-26113 Catalog#: A-1157
         AP-26113 is a novel potent ALK inhibitor.
ARN-509 Catalog#: A-6036
         Apalutamide, also known as ARN-509 and JNJ-56021927 , is an androgen receptor antagonist
ARQ-087 Catalog#: A-6001
         ARQ-087 is a Pan inhibitor of the fibroblast growth factor receptor (FGFR)
ARQ-092 Catalog#: A-1604
         ARQ 092 is a AKT inhibitor, is also an orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity.
ARQ-197(Tivantinib) Catalog#: A-1109
         ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase
ARQ-621 Catalog#: A-1605
         ARQ-621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division.
ARQ-736 Catalog#: A-1606
ARRAY-614 Catalog#: A-1404
         ARRAY-614 is a p38/Tie-2 inhibitor.
ARRY-380 Catalog#: A-1177
         ARRY-380 is an orally active, reversible and selective ErbB-2 inhibitor
ARRY-382 Catalog#: A-1607
         ARRY-382 is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; cFMS) with potential antineoplastic activity.
ARRY-520 Catalog#: A-1305
         ARRY-520 is a Kinesin Spindle Protein (KSP) inhibitor which has sub-nanomolar potency in both enzymatic and cellular assays and is anti-mitotic, leading to cancer cell death.
ARRY-614 Catalog#: A-1410
         ARRY-614 is an orally active p38/Tie2 inhibitor.
ARRY-797 Catalog#: A-1409
         ARRY-797 is a selective p38 kinase inhibitor.
AS-703026(MSC-1936369) Catalog#: A-1005
         AS-703026 is an MEK inhibitor.
ASA-404 Catalog#: A-1142
         ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA)
ASP-3026 Catalog#: A-1171
         ASP-3026 is an ALK inhibitor.
ASP-5878 Catalog#: A-6093
         ASP-5878 is a selective FGFR inhibitor.
ASP-8273 Catalog#: A-1394
         ASP-8273 is an EGFR tyrosine kinase inhibitor.
ASP-9603 Catalog#: A-1608
AST1306 Catalog#: A-9065
         AST1306 is a novel anilino-quinazoline compound, which inhibits the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems.
AT-13148 Catalog#: A-1413
         AT-13148 is an orally active small molecule inhibitor of PKB/Akt and p70S6 kinase.
AT-13387 Catalog#: A-1247
         AT-13387 is a selective potent Hsp90 inhibitor in clinic trials.
AT-406 Catalog#: A-1207
         AT-406 is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs).
AT-7519 Catalog#: A-1921
AT-9283 Catalog#: A-1609
         AT9283 is a multikinase inhibitor, is also a small-molecule inhibitor of several kinases with potential antineoplastic activity.
AV-951(Tivozanib) Catalog#: A-1118
         AV-951 is a potent and selective inhibitor of VEGFR-1, 2 & 3 kinases.
Avitinib Catalog#: A-6088
         Avitinib is a selective EGFR inhibitor.
Avitinib Maleate Catalog#: A-6109
         Avitinib Maleate is a selective EGFR inhibitor.
AVL-292 Catalog#: A-1299
         AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
AXL-1717 Catalog#: A-1414
         AXL-1717 is a oral IGF-1R inhibitor.
AZ-505 Catalog#: A-1976
         AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2(IC50=0.12 uM) with potential anticancer activity, >600 fold than SMYD3(IC50>83.3 uM); DOT1L(IC50>83.3 uM);EZH2(IC50>83.3 uM).
AZ-5104 Catalog#: A-9100
         AZ5104 is a demethylated metabolite of AZD-9291. AZ-5104 was identified to exhibit 5-fold potency compared to AZD-9291, which is currently in clinical trial
AZ-628 Catalog#: A-9011
         AZ-628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.
AZD-0156 Catalog#: A-6008
         AZD-0156 is an oral, potent and selective ATM kinase inhibitor in clinical trials
AZD-0530 Catalog#: A-1006
AZD-1208 Catalog#: A-1501
         AZD1208 is a Novel, Potent and Selective Pan PIM Kinase Inhibitor.
AZD-1480 Catalog#: A-1135
         AZD-1480 is a potent JAK2 inhibitor (IC50 = 260 pM)
AZD-2014 Catalog#: A-1090
         AZD-2014 is a mTOR inhibitor in clinical trials
AZD-2281 (Olaparib) Catalog#: A-1125
         Highly potent, oral and selective inhibitor of poly(ADP-ribose) polymerase (PARP)
AZD-3147 Catalog#: A-1386
         A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2.
AZD-3463 Catalog#: A-1403
         AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib.
AZD-3514 Catalog#: A-1232
         AZD-3514 is an androgen receptor in clinic trials.
AZD-3759 Catalog#: A-1395
         AZD-3759 is an EGFR tyrosine kinase inhibitor.
AZD-3965 Catalog#: A-1374
         AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.
AZD-4547 Catalog#: A-1174
         AZD-4547 is a FGFR inhibitor.
AZD-4635 Catalog#: A-6094
         AZD-4635 is a selective PI3Kd inhibitor.
AZD-5363 Catalog#: A-1183
         AZD5363 is an AKT inhibitor.
AZD-5438 Catalog#: A-1617
         AZD-5438 CAS.602306-29-6
AZD-5582 Catalog#: A-9051
         AZD5582 is a potent IAP inhibitor, which is a dimeric compound based on the AVPI motif of Smac.
AZD-5991 Catalog#: A-6097
         AZD-5991 is a selective MCL-1 inhibitor.
AZD-6094 (HMPL-504, Volitinib) Catalog#: A-1316
         AZD-6094 is a potent and selective c-MET inhibitor.
AZD-6244(ARRY-142886, Selumetinib) Catalog#: A-1007
         AZD-6244 is a novel inhibitor of MEK1/2 kinases,effectively inhibited the proliferation of acute biphenotypic leukemia MV4-11 and acute monocytic leukemia MOLM13 cells
AZD-6738 Catalog#: A-1221
         AZD-6738 is potent and selective inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase.
AZD-7762 Catalog#: A-1116
         AZD-7762 is a checkpoint kinase inhibitor in clinical trials.
AZD-8055 Catalog#: A-1008
         AZD-8055 is an mTORC1/C2 inhibitor with an IC50 of 0.8 nmol/L, in clinical trials
AZD-8186 Catalog#: A-1610
         AZD8186 is a novel potent small molecule that targets the lipid kinase PI3K. with selectivity vs PI3K.
AZD-8330 Catalog#: A-1245
         AZD8330 is an orally active, selective MEK inhibitor in clinic trials.
AZD-8835 Catalog#: A-1517
         An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity.
AZD-8931 Catalog#: A-1197
         AZD8931 is a potent, reversible, small-molecule inhibitor against ErbB1 , ErbB2 and ErbB3 kinases.
AZD-9496 Catalog#: A-1511
         AZD-9496 is an oral, selective estrogen receptor down-regulator (SERD)
AZD1152-HQPA(Barasertib) Catalog#: A-1377
         AZD1152-HQPA (Barasertib) is a highly potent and selective Aurora B inhibitor with a Ki of 0.36 nM.
b-AP15 Catalog#: A-1194
         b-AP15 is a novel inhibitor of proteasome activity, with a different mechanism of action than the available and widely used proteasome inhibitors such as bortezomib.
BAY-1000394 Catalog#: A-1408
         BAY-1000394 is an oral CDK inhibitor.
BAY-1082439 Catalog#: A-6042
         BAY-1082439 inhibitor of PI3K alpha and beta isoforms.
BAY-1125976 Catalog#: A-6010
         BAY-1125976 is an inhibitor of the serine/threonine protein kinase AKT (protein kinase B) isoforms 1 and 2 (AKT1/2)
BAY-1143572 Catalog#: A-1514
BAY-1161909 Catalog#: A-6095
         BAY-1161909 is a selective MPS1 inhibitor.
BAY-1251152 Catalog#: A-6085
         BAY-1251152 is a selective CDK9 inhibitor.
BAY-1436032 Catalog#: A-6039
         BAY-1436032 is an inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1)
BAY-1895344 Catalog#: A-6070
         BAY-1895344 is a selective ATR inhibitor.
BAY-6356 Catalog#: A-9066
         BAY-6356 is a bromodomain protein 4 (BRD4) inhibitor in preclinical development.
BAY-869766 (RDEA-119) Catalog#: A-1036
         BAY-869766 (RDEA-119) is a potent and highly selective MEK Inhibitor
BAY-876 Catalog#: A-6009
         BAY-876 is a Glucose transporter type 1 (GLUT-1) inhibitors
BAY57-1293 Catalog#: A-1935
         BAY 57-1293 is a potent helicase primase inhibitor
BAY73-4506 (Regorafenib) Catalog#: A-1112
         Regorafenib (BAY73-4506) is an oral multikinase inhibitor, including B-Raf (IC50, 69 nM), c-KIT (IC 50, 17 nM), VEGFR2 (IC50, 40nM)
BAY87-2243 Catalog#: A-1178
Bedaquiline Catalog#: A-1946
         Bedaquiline (trade name Sirturo, code names TMC207 and R207910) is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica.
Benzamide Riboside Catalog#: A-1322
         Benzamide riboside is an inhibitor of IMP dehydrogenase (IMPDH) which exhibits oncolytic activity.
BET-BAY-002 Catalog#: A-1361
BEZ-235 Catalog#: A-1009
         BEZ-235 is a PI3K/mTOR inhibitor in clinical trials
BGB-283 Catalog#: A-6002
         BGB-283 is an inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR)
BGB-290 Catalog#: A-6108
         BGB-290 is a selective PARP inhibitor.
BGB-324 Catalog#: A-6103
         BGB-324 is a selective AXL inhibitor.
BGJ-398 Catalog#: A-1143
         NVP-BGJ398 is an FGFR kinase inhibitor
BGT-226 Catalog#: A-1070
         BGT-226 is a PI3K/mTOR inhibitor in clinical trials
BI-1482694(HM61713) Catalog#: A-1964
BI-2536 Catalog#: A-1010
         BI-2536 is a potent inhibitor of the mitotic kinase plk1. It causes mitotic arrest and induces apoptosis in human cell lines of various origin and has progressed into clinical trials (1,2).
BI-6727 Catalog#: A-1187
         BI6727 is a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity.
BIBF-1120 Catalog#: A-1347
         Nintedanib (BIBF 1120) is a potent inhibitor of triple angiokinase for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
BKM-120 Catalog#: A-1108
         BKM-120 is a PI3K inhibitor in clinical trials.
BLU-554 Catalog#: A-6071
         BLU-554 is a selective FGFR4 inhibitor.
BLU-9931 Catalog#: A-1397
         BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM)
BMS-536924 Catalog#: A-1011
         BMS-536924 is an inhibitor of the IGF-IR (IC50 = 100 nM), InsR and fokal adhesion kinase
BMS-599626 Catalog#: A-1012
         BMS-599626 is a pan-HER Kinase Inhibitor
BMS-708163 Catalog#: A-1261
         BMS-708163 is a Potent, Selective and Orally Bioavailable gamma-secretase Inhibitor.
BMS-754807 Catalog#: A-1013
         BMS-754807 is an IGF-1R inhibitor, in phase I clinical trials
BMS-777607 Catalog#: A-1155
         BMS-777607 is a Small-Molecule Met Kinase Inhibitor.
BMS-833923(XL-139) Catalog#: A-1700
         BMS-833923 (or XL-139) is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity.
BMS-863233(XL-413) Catalog#: A-1072
         BMS-863233 (XL-413) is a CDC7 inhibitor in clinical trials.
BMS-906024 Catalog#: A-1401
         BMS-906024 is a pan Notch inhibitor.
BMS-911543 Catalog#: A-1175
         BMS-911543 is a JAK2 Inhibitor.
BMS-983970 Catalog#: A-1359
BMS-986115 Catalog#: A-6091
         BMS-986115 is a selective Notch inhibitor.
BMS-986158 Catalog#: A-6072
         BMS-986158 is a selective BET inhibitor.
BMS-986205 Catalog#: A-6067
         BMS-986205 is a selective IDO1 inhibitor.
Bortezomib (PS-341) Catalog#: A-1014
         Bortezomib (PS-341) is a proteasome inhibitor
Bosutinib Catalog#: A-9060
         Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity.
Brivanib(BMS-582664) Catalog#: A-1160
         Brivanib(BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
BVD-523 Catalog#: A-1378
         ERK inhibitor BVD-523 An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity.
BYL-719 Catalog#: A-1214
         BYL719 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
Cardiogenol C HCl Catalog#: A-1957
         Cardiogenol C is a diaminopyrimidine compound that induces the differentiation of MHC- (myosin heavy chain) positive cardiomyocytes from embryonic stem cells with an EC50 value of 0.1 µM.
CB-1158 Catalog#: A-6098
         CB-1158 is a selective Arginase inhibitor.
CB-5083 Catalog#: A-1513
         CB-5083 is an orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity.
CC-115 Catalog#: A-1970
         CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity.
CCT-007093 Catalog#: A-1346
         CCT007093 is a potent PPM1D inhibitor or WIP1 inhibitor that selectively reduces viability of human tumour cell lines
CCT-251545 Catalog#: A-1387
         a potent small-molecule inhibitor of WNT
CCT-251921 Catalog#: A-6003
         CCT-251921 is a potent selective inhibitor of the mediator complex-associated cyclin-dependent kinase CDK8 and CD19.
Cediranib(AZD-2171) Catalog#: A-1161
         Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.
Celecoxib Catalog#: A-9040
         Celecoxib is a highly selective COX-2 inhibitor and primarily inhibits prostaglandin production.
CEP-18770 Catalog#: A-1095
         CEP-18770 is a Proteasome inhibitor in clinical trials
CEP-32496 Catalog#: A-1310
         CEP-32496 is an oral small molecule kinase inhibitor of V600E mutated B-RAF.
CEP-37440 Catalog#: A-1300
         CEP-37440 is a selective dual ALK-FAK inhibitor, provided by Cephalon to determine the activity or response in potential clinical indications.
CEP-40783 Catalog#: A-6052
         CEP-40783 is a selective AXL inhibitor.
CEP-9722 Catalog#: A-1188
         CEP-9722 is a PARP inhibitor.
CFI-400945 (Free Base) Catalog#: A-6005
         CFI-400945 (Free Base) CFI-400945 is an a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity..
CGI-1746 Catalog#: A-1955
         CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.
CGM-097 Catalog#: A-1315
         CGM-097 is a potent and selective MDM2 inhibitor.
CH-5132799 Catalog#: A-1215
         CH5132799, a novel class I PI3K inhibitor, exhibited a strong inhibitory activity especially against PI3Kα (IC(50)=0.014 μM).
CH-5424802 (RG-7853, AF-802) Catalog#: A-1176
         CH5424802 is a potent and selective ALK inhibitor
CHR-3996 Catalog#: A-1082
         CHR-3996 is a HDAC inhibitor in clinical trials
CHS-828(GMX-1778) Catalog#: A-1954
         CHS-828, also known as GMX-1778, is a potent and selective NAMPT inhibitor.
CI-1033 Catalog#: A-1015
         CI-1033is an inhibitor of EGFR , HER-2 and ErbB-4
CI-1040(PD 184352) Catalog#: A-1064
         ATP-noncompetitive MEK inhibitor
         Cilengitide is a cyclic arginine-glycine-aspartic acid peptide that targets avß3 integrin, expressed on neovasculature.
CNX-1351 Catalog#: A-1337
         CNX-1351 is a selective covalent Inhibitor of PI3Kα
CO-1686 Catalog#: A-1621
         CO-1686 inhibits mutated EGFR including T790M, but ignores the wild type EGFR. CO-1686 shows promising clinical efficacy in patient tumors.
CP-1203 Catalog#: A-9065
         CP-1203 is a BET proteins inhibitor in preclinical development.
CP-868596 Catalog#: A-1519
         Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-K
CPI-0610 Catalog#: A-1515
         CPI-0610 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity.
CPI-203 Catalog#: A-1289
         CPI203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay).
CPI-444 Catalog#: A-6099
         CPI-444 is a selective A2A inhibitor.
Cyclopamine Catalog#: A-1057
         Cyclopamine is a hegehog pathway inhibitor.
Dabrafenib (free base) (GSK2118436A) Catalog#: A-1220
         Dabrafenib (free base) (GSK2118436A) is a B-Raf inhibitor carrying V600E mutation
Dabrafenib Mesylate (GSK-2118436B) Catalog#: A-1219
         GSK2118436 (dabrafenib) is a selective ATP-competitive BRAF inhibitor
Dacomitinib (PF-00299804) Catalog#: A-1246
         Dacomitinib (PF-00299804) is an oral, pan-HER inhibitor in clinic trials.
Debio-1347 (CH-5183284) Catalog#: A-1332
         CH-5183284 is a selective FGFR 1, 2, 3 inhibitor.
Defactinib (VS-6063, PF-04554878) Catalog#: A-1079
         PF-04554878 is a FAK inhibitor in clinical trials
Desvenlafaxine succinate Catalog#: A9038
         Desvenlafaxine is a synthetic form of the isolated major active metabolite of venlafaxine, and is categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI)
DM1-SMCC Catalog#: A-1947
         DM1-SMCC CAS No.1228105-51-8
Docetaxel Catalog#: A-1914
         Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug
E-7090 Catalog#: A-6063
         E-7090 is a selective FGFR inhibitor.
E-7449 Catalog#: A-1358
         An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity.
E-7820 Catalog#: A-1283
         E-7820 is a small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities.
eFT508 HCl Catalog#: A-6030
         eFT508 (HCl salt) is first-in-class, orally available, potent inhibitor of mitogen-activated protein kinase (MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic activity.
EGF-816 Catalog#: A-1392
         EGF-816 is an EGFR tyrosine kinase inhibitor.
EMD-1214063 Catalog#: A-1087
         EMD-1214063 is a c-Met inhibitor in clinical trials
ENMD-2076 Catalog#: A-1250
         ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases.
EPZ-004777 Catalog#: A-1801
         EPZ004777 is a potent, selective inhibitor of DOT1L.
EPZ-005687 Catalog#: A-1415
         EPZ-005687 is a selective EZH2 inhibitor.
EPZ-015666 Catalog#: A-1516
         first-in-class PRMT5 inhibitor EPZ015666
EPZ-020411 Catalog#: A-1962
EPZ-5676 Catalog#: A-1701
         EPZ-5676 is a small molecule inhibitor of histone methyltransferase with potential antineoplastic activity.
EPZ-5687 Catalog#: A-1622
EPZ-6438 (E-7438) Catalog#: A-1623
         EPZ-6438 (E-7438)
FGF-401 Catalog#: A-6073
         FGF-401 is a selective FGFR4 inhibitor.
FK-866 Catalog#: A-1303
         FK-866 has been shown to induce apoptosis by non-competitive, and specific inhibition of nicotamide phosphoribosyltransferase (NAMPT).
Fluvastatin Catalog#: A-9034
         Fluvastatin is an HMGCR (HMG-CoA reductase) inhibitor.
FV-225 Catalog#: A-1388
         FV-225 is is an EGFR tyrosine kinase inhibitor.
G1T28(Trilaciclib) Catalog#: A-6065
         G1T28(Trilaciclib) is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy.
Garenoxacin Catalog#: A-1948
GDC-0032 Catalog#: A-1236
         GDC-0032 is a potent PI3K inhibitor in clinical trials.
GDC-0068 Catalog#: A-1205
         GDC-0068 is a highly selective ATP-competitive pan-Akt inhibitor that inhibits all three isoforms of Akt with IC50 values of 5 to 30 nM.
GDC-0084 Catalog#: A-6015
         GDC-0084 is a phosphatidylinositol 3-kinase (PI3K) inhibitor
GDC-0152 Catalog#: A-1418
         GDC-0152 is a second mitochondrial activator of caspases (Smac) mimetic inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity.
GDC-0349 Catalog#: A-1619
         GDC-0349 CAS.1207360-89-1
GDC-0449 Catalog#: A-1113
         GDC-0449 is an orally-administered small molecule antagonist of Hedgehog signaling pathway.
GDC-0575 Catalog#: A-6101
         GDC-0575 is a selective CHK1 inhibitor.
GDC-0623 Catalog#: A-1181
         GDC-0623 is an MEK inhibitor.
GDC-0810 (ARN-810) Catalog#: A-9049
         GDC-0810 (ARN-810) is an orally bioavailable selective estrogen receptor degrader (SERD) with IC50 of 0.7 nM.
GDC-0853 Catalog#: A-6074
         GDC-0853 is a selective BTK inhibitor.
GDC-0917 (CUDC-427) Catalog#: A-1235
         GDC-0917 (CUDC-427) is an orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity.
GDC-0917(CUDC-427) Catalog#: A-1235
         GDC-0917 is a potent IAP antagonist in clinical trials.
GDC-0919 Catalog#: A-6083
         GDC-0919 is a selective IDO1 inhibitor.
GDC-0941 Catalog#: A-1017
         GDC-0941 is a PI3K inhibitor
GDC-0973(XL-518) Catalog#: A-1180
         XL-518 is a potent selective orally bioavailable MEK1 inhibitor.
GDC-0980 Catalog#: A-1069
         GDC-0980 is a PI3K/mTOR inhibitor in clinical trials
GDC-0994 Catalog#: A-1318
         GDC-0994 is a potent and selective Erk1/2 inhibitor.
GDC-5573 Catalog#: A-6102
         GDC-5573 is a selective RAF inhibitor.
Gilteritinib (ASP2215) Catalog#: A-1371
         Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.
GKT-137831 Catalog#: A-1381
         GKT137831 is the first in class NOX1/4 inhibitor.
Gleevec (STI-571) Catalog#: A-1018
         Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec,
GLPG-0634(Filgtinib) Catalog#: A-1338
         GLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases.
GNE-0877 Catalog#: A-1335
         GNE-0877 is a highly potent and selective LRRK2 inhibitor.
GNE-9605 Catalog#: A-1372
         GNE-9605 is a highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
GR148672X Catalog#: A-1375
GS-1101(CAL-101) Catalog#: A-1138
         CAL-101 is an Oral Delta Isoform-Selective PI3 Kinase Inhibitor.
GS-566500 Catalog#: A-1950
GS-5829 Catalog#: A-9064
         GS-5829 is a BET inhibitor in phase I.
GS-9901 Catalog#: A-6087
         GS-9901 is a selective PI3Kd inhibitor.
GS-9973 Catalog#: A-1321
         GS-9973 is an oral inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity.
GSK-1059615 Catalog#: A-1216
         GSK-1059615 is a pan-PI3K reversible inhibitor with IC50s against PI3Kα (0.4 nM), PI3Kβ (0.6 nM), γ(5 nM), and δ(2 nM) as well as mTOR(12 nM).
GSK-1070916 Catalog#: A-1351
         GSK1070916 is a novel ATP competitive inhibitor that is highly potent and selective for Aurora B/C kinases.
GSK-1120212(Trametinib,JTP-74057) Catalog#: A-1258
         GSK-1120212(Trametinib, JTP-74057) is a MEK inhibitor in clinical trials
GSK-1292263 Catalog#: A-1614
         GSK-2126458 CAS.1086062-66-9
GSK-1324726A/I-BET-726 Catalog#: A-1369
         GSK1324726A (I-BET726) is a novel, potent, and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50= 41 nM), BRD3 (IC50= 31 nM), and BRD4 (IC50= 22 nM).
GSK-1363089 (XL-880) Catalog#: A-1086
         GSK-1363089 (XL-880) is a c-Met inhibitor in clinical trials
GSK-1904529A Catalog#: A-1249
         GSK1904529A, is a inhibitor of IGF-IR (IC50= 27 nM) and IR (IC50= 25 nM).
GSK-2110183 Catalog#: A-1503
         GSK-2110183 is an orally bioavailable AKT inhibitor.
GSK-2126458 Catalog#: A-1067
         GSK-2126458 is a PI3K/mTOR inhibitor in clinical trials
GSK-2141795 Catalog#: A-1504
         GSK-2141795 is an orally bioavailable AKT inhibitor.
GSK-2194069 Catalog#: A-6000
         GSK-2194069 is a fatty acid synthase (FAS) inhibitors
GSK-2256098 Catalog#: A-1078
         GSK-2256098 is a FAK inhibitor in clinical trials
GSK-2606414 Catalog#: A-1307
         GSK2606414 is an orally available, potent, and selective PERK inhibitor.
GSK-2636771 Catalog#: A-1230
         GSK-2636711 is a PI3K-beta selective inhibitor in clinical trials
GSK-2830371 Catalog#: A-1320
         GSK2830371 is a orally active, allosteric inhibitor of Wip1 phosphatase with IC50 of 6 nM.
GSK-2879552 Catalog#: A-1385
         GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
GSK-3326595 Catalog#: A-6068
         GSK-3326595 is a selective PRMT5 inhibitor.
GSK-343 Catalog#: A-1416
         GSK-343 is a potent EZH2 inhibitor.
GSK-610677 Catalog#: A-1413
         GSK-610677 is a p38 kinase inhibitor.
GSK-690693 Catalog#: A-1020
         GSK-690693 is an inhibit of Akt kinases 1, 2, and 3
GSK-923295 Catalog#: A-1966
         GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E) with Ki value of 3.2 nM.
GSK126 Catalog#: A-1275
         GSK126 is a highly potent and selective small molecule inhibitor of histone methyltransferase EZH2.
GSK1838705A Catalog#: A-1800
         GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively.
GW-572016 Catalog#: A-1021
         GW-572016 is an inhibitor of EGFR(Ki=3nM),ErbB-2(Ki=13nM),ErbB-4(Ki=347nM)
H-1152 Catalog#: A-1293
         H-1152 is a potent, specific, ATP-competitive, and cell permeable inhibitor of ROCK
H3B-6527 Catalog#: A-6107
         H3B-6527 is a selective FGFR4 inhibitor.
HDM-201 Catalog#: A-6016
         HDM-201 is a human double minute 2 homolog (HDM2) inhibitor
HM-61713 Catalog#: A-1331
         HM-61713 is an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.
HM-781-36B Catalog#: A-1393
         HM-781-36B is an EGFR tyrosine kinase inhibitor.
HSP-990 Catalog#: A-1144
         HSP990 is an orally available Hsp90 inhibitor
Hydrogen bromide Prasugrel acetate Catalog#: A-9044
         Hydrogen bromide Prasugrel acetate
I-BET-762(GSK-525762) Catalog#: A-1286
         GSK-525762 is a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity.
I-BET151 (GSK1210151A) Catalog#: A-1290
         GSK1210151A (I-BET151) is an inhibitor of the BET (bromodomain and extra terminal domain protein) family of acetyl-lysine recognizing, chromatin ′adaptor′ proteins.
Ibrutinib Catalog#: A-1383
         Ibrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
ICG-001 Catalog#: A-6028
         ICG-001 is a potent and selective inhibitor against CBP and beta-catenin binding interaction in cancer stem cells.
Idarubicin Hcl Catalog#: A-1296
         Idarubicin Hydrochloride is the hydrochloride salt preparation of Idarubicin (IDA) (sc-204774), an anthracycline and an analog of daunorubicin (sc-218089).
INC-280 Catalog#: A-1145
         Oral, highly selective c-Met receptor tyrosine kinase (RTK) inhibitor
INC-424 Catalog#: A-1146
         An oral, Janus kinase (JAK) inhibitor selective for JAK1 and JAK2
INCB-018424(Ruxolitinib) Catalog#: A-1134
         INCB018424 is an oral, selective JAK inhibitor
INCB-039110 Catalog#: A-6096
         INCB-039110 is a selective JAK1 inhibitor.
INCB-24360 Catalog#: A-1521
         INCB-24360 is an orally administered, novel, potent and selective indoleamine dioxygenase (IDO) inhibitor.
INK-1197 Catalog#: A-1133
         INK-1197 is an orally available dual delta/gamma-specific inhibitor of PI3K.
IPI-145 Catalog#: A-1274
         IPI-145 is a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
IPI-269609 Catalog#: A-1063
         An orally bioavailable small-molecule inhibitor of Hedgehog
IPI-549 Catalog#: A-6041
         IPI-549 is an inhibitor of PI3K
IPI-926 Catalog#: A-1062
         IPI-926 is a novel, potent, orally-available small molecule inhibitor of the Hedgehog pathway.
Iressa (Gefitinib) Catalog#: A-1024
         Iressa is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which was approved for cancer treatment by FDA.
ITF-2357 Catalog#: A-1186
         ITF2357 is a noverl HDAC inhibitor.
JNJ-26481585 Catalog#: A-1162
         JNJ-26481585 is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of HDAC with potential antineoplastic activity.
JNJ-26483327 (free base) Catalog#: A-1357
         An orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity.
JNJ-31020028 Catalog#: A-1953
         JNJ-31020028 is a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor.
JNJ-38877605 Catalog#: A-1119
         JNJ-38877605 is an orally available selective c-Met inhibitor in clinical.
JNJ-38877618 Catalog#: A-6091
         JNJ-38877618 is a selective HGFR inhibitor.
JNJ-42756493 Catalog#: A-6106
         JNJ-42756493 is a selective FGFR inhibitor.
JNJ-47117096 Catalog#: A-1360
JPH-203 Catalog#: A-6077
         JPH-203 is a potent and selective LAT1 selective inhibitor.
KPT-330 Catalog#: A-6034
         Selinexor (KPT-330) is an inhibitor of XPO1, or CRM1 (chromosome region maintenance 1 protein)
KPT-8602 Catalog#: A-6035
         KPT-8602 is an inhibitor of exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1)
KRP-203 Catalog#: A-1213
         KRP-203 is an EDG3 inhibitor in clinical trials.
KU-0063794 Catalog#: A-1124
         Selective inhibitor of mammalian target of rapamycin (mTOR)
KU-55933 Catalog#: A-1930
         KU-55933 is a very potent, specific inhibitor of Ataxia telangiectasia (A-T) mutated (ATM) kinase (IC50 = 13 nM).
KW-2478 Catalog#: A-1115
         KW-2478 is an Hsp90 inhibitor in clinical trials.
Lapatinib Catalog#: A-1319
         Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
LBH-589 Catalog#: A-1025
         LBH-589 is a highly potent deacetylase inhibitor shown to impede multiple pathways implicated in cancer associated with cutaneous T-cell lymphoma and other challenging malignancies.
LBW-242 Catalog#: A-1420
         LBW242 is a Smac mimetic, and potent IAP inhibitor.
LCL-161 Catalog#: A-1147
         Promoting cancer cell death by deactivating inhibitor of apoptosis proteins (IAPs)
LDK-378 Catalog#: A-1189
         LDK-378 is an ALK inhibitor.
LEE-011 Catalog#: A-1277
         LEE011 is a new oral drug designed to inhibit the activity of an enzyme known as CDK4/6.
LEQ-506 Catalog#: A-1276
         LEQ506 is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity.
Levetiracetam Catalog#: A-9039
         Levetiracetam is a pyrrolidine with antiepileptic activity.
LGH-447 Catalog#: A-1512
         LGH447 is an orally available pan-PIM protein kinase inhibitor with potential antineoplastic activity.
LGK-974 Catalog#: A-1400
         LGK-974 is a selective porcupine inhibitor targeting Wnt signaling in cancer.
Linagliptin Catalog#: A-9041
         Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
LOR-253 Catalog#: A-1421
         LOR-253 HCl is the hydrochloride salt of a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1) with potential antitumor activity.
LOXO-101 Catalog#: A-9048
         LOXO-101 is an orally bioavailable, potent, ATP-competitive inhibitor of TRKA, TRKB, and TRKC.
LOXO-195 Catalog#: A-6100
         LOXO-195 is a selective A2A inhibitor.
Lucitanib Catalog#: A-1364
         Lucitanib, also known as E-3810, is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity.
Lucitanib(E-3810) Catalog#: A-1268
         E-3810 is a potent dual inhibitor of VEGFR and FGFR.
LXS-196 Catalog#: A-6075
         LXS-196 is a selective PKC inhibitor.
LY-2090314 Catalog#: A-1239
         LY-2090314 is a potent GSK3-beta inhibitor in clinical trials.
LY-2157299 Catalog#: A-1616
         LY-2157299 CAS.700874-72-2
LY-2228820 Catalog#: A-1265
         LY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM.
LY-2334737 Catalog#: A-1702
         LY2334737 is an oral gemcitabine prodrug in which gemcitabine is linked to valproic acid via an amide bond, enabling it to bypass hydrolysis in enterocytes and portal circulation, thereby avoiding the extensive first pass metabolism that occurs with unmodified gemcitabine.
LY-2523355 Catalog#: A-1271
         LY-2523355 is an allosteric inhibitor of Eg5 which selectively inhibits bipolar mitotic spindle formation.
LY-2603618 Catalog#: A-1240
         LY-2603618 is a potent CHK1 inhibitor in clinical trials.
LY-2606368 Catalog#: A-1703
         LY2606368 is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.
LY-2608204 Catalog#: A-1959
         LY2608204 is a potent activator of glucokinase (GK) with EC₅₀ of 42 nM. Potential antidiabetic agent to treat type 2 diabetes.
LY-2780301 Catalog#: A-1237
         LY-2780301 is a potent p70S6K/AKT dual inhibitor in clinical trials
LY-2784544 Catalog#: A-1170
         LY2784544 is a small molecule selective mutant JAK2 kinase inhibitor.
LY-2835219 Catalog#: A-1407
         LY-2835219 is a CDK 4/6 dual Inhibitor.
LY-2874455 Catalog#: A-1198
         LY2874455 is a Novel FGF/FGFR Inhibitor.
LY-2875358 Catalog#: A-1313
         anti-c-MET monoclonal antibody LY2875358
LY-2886721 Catalog#: A-1958
         LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.
LY-294002 Catalog#: A-6111
         LY-294002 is a selective PI3K inhibitor.
LY-2940680 Catalog#: A-1248
         LY-2940680 is a Hedgehog inhibitor in clinical trials.
LY-3007113 Catalog#: A-1411
         LY-3007113 is a p38 MAPK Inhibitor.
LY-3009120 Catalog#: A-1317
         LY03009120 is a potent and selective pan-Raf inhibitor.
LY-3023414 Catalog#: A-1704
LY-3039478 Catalog#: A-1705
LY-3154567 Catalog#: A-1963
LY-3200882 Catalog#: A-6084
         LY-3200882 is a selective TGFBR1 inhibitor.
LY-3214996 Catalog#: A-6069
         LY-3214996 is a selective ERK1/2 inhibitor.
LY-450139 Catalog#: A-1262
         Semagacestat (LY450139) is a novel gamma-secretase inhibitor.
LY-900009 Catalog#: A-1238
         LY-900009 is a potent Notch inhibitor in clinical trials.
LY2801653 Catalog#: A-1182
         LY2801653 is a c-Met inhibitor.
LY411575 Catalog#: A-1615
         LY411575 CAS:209984-57-6
M-3814 Catalog#: A-6076
         M-3814 is a selective DNA-PK inhibitor.
M-9831 Catalog#: A-6086
         M-9831 is a selective DNA-PK inhibitor.
Masatinib (AB-1010) Catalog#: A-1272
         Masatinib (AB-1010) has greater potency and selectivity for the wild-type c-Kit receptor and constitutively activated mutant forms found in gastrointestinal stromal tumors (GIST) and other human diseases.
MEK-162 (ARRY-162) Catalog#: A-1128
         MEK-162(ARRY-162) is an MEK inhibitor in clinical trials
MGCD-0103 (Mocetinostat) Catalog#: A-1106
         MGCD-0103 (Mocetinostat) is HDAC inhibitor, and inhibits Class 1 isoforms of HDAC,specifically HDAC 1(IC50=0.15umol/l), 2(IC50=0.29umol/l) and3(IC50=1.66umol/l).
MGCD-265 Catalog#: A-1973
         MGCD265 is a multitargeted tyrosine kinase inhibitor, which is also a n orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity.
MGCD-516(Sitravatinib) Catalog#: A-1974
         Sitravatinib, also known as MGCD516 or MG516, is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth.
MI-503 Catalog#: A-1399
         MI-503 and MI-463 Demonstrate Selective and On-Target Activity in MLL Leukemia Cells
MIDOSTAURIN(PKC412) Catalog#: A-1348
         PKC412 (midostaurin) is an oral multi-targeted kinase inhibitor
MK-0731 Catalog#: A-1298
         MK-0731 is a synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP.
MK-0752 Catalog#: A-1259
         MK-0752 is a potent gamma secretase inhibitor in clinical development (IC50 ~50 nM).
MK-1775 Catalog#: A-1117
         MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.
MK-2206 Catalog#: A-1206
         MK-2206 is an oral potent allosteric Akt inhibitor (IC50=8nM,2nM,65nM for Akt1 Akt2 and Akt3 resp.)
MK-2206(Dihydrochloride salt) Catalog#: A-1909
         MK-2206 is an oral potent allosteric Akt inhibitor (IC50=8nM,2nM,65nM for Akt1 Akt2 and Akt3 resp.)
MK-470 Catalog#: A-1199
         MK-470 is an SYK inhibitor.
MK-4827 Catalog#: A-1092
         MK-4827 is a PARP inhibitor in clinical trials
MK-4827-HCL Catalog#: A-6032
         MK-4827 is an inhibitor of PARP 1 and 2
MK-8033 Catalog#: A-1107
         MK-8033 is a c-MET inhibitor in clinical trials
MK-8353 (SCH-900353) Catalog#: A-1191
         MK-8353 (SCH-900353) is an ERK1 inhibitor.
MK-8669 (AP-23573, Deforolimus) Catalog#: A-1004
         MK-8669 (AP-23573, Deforolimus) is an mTOR inhibitor.
MLN-0128(INK-128) Catalog#: A-1023
         MLN-0128(INK-128) is an mTORC1/C2 inhibitor
MLN-1117 Catalog#: A-6082
         MLN-1117 is a selective PI3K inhibitor.
MLN-2238 Catalog#: A-1226
         MLN2238 is a potent reversible and specific beta5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM.
MLN-2480 Catalog#: A-1192
         MLN -2480 is a pan Raf inhibitor in chinical trials.
MLN-4924 Catalog#: A-1139
         MLN4924 is a novel NAE inhibitor, on blood and skin.
MLN-7243 Catalog#: A-1384
         MLN7243 is a small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity. UAE inhibitor MLN7243 binds to and inhibits UAE, which prevents both protein ubiquitination and subsequent protein degradation by the proteasome.
MLN-8237 Catalog#: A-1123
         MLN8237 is a second-generation, selective AAK inhibitor.
MLN-9708 Catalog#: A-1097
         MLN-9708 is a Proteasome inhibitor in clinical trials
Molidustat(BAY85-3934) Catalog#: A-1945
         Molidustat, also known as BAY 85-3934, is a novel inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells.
MPI-0479605 Catalog#: A-1524
         MPI-0479605 is a potent and selective ATP competitive inhibitor of Mps1.
MS-275 (Entinostat) Catalog#: A-1059
         MS-275 is a histone deacetylase inhibitor.
Napabucasin Catalog#: A-1960
         Napabucasin is an orally-administered small molecule which can block cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells.
NMS-1116354 Catalog#: A-1073
         NMS-1116354 is a CDC7 inhibitor in clinical trials.
NMS-1286937 Catalog#: A-1094
         NMS-1286937 is a PLK inhibitor in clinical trials
NMS-873 Catalog#: A-1308
         NMS-873 is an potent, allosteric and specific VCP inhibitor (also known as p97 inhibitor) with IC50 of 30 nM.
NPI-0052 Catalog#: A-1141
         NPI-0052 is a novel proteasome inhibitor.
NV-128 Catalog#: A-1027
         NV-128 is an mTOR inhibitor
NVP-AEW541 Catalog#: A-1911
         NVP-AEW541 is an IGF-IR inhibitor in clinic trials.
NVP-AUY-922 Catalog#: A-1111
         NVP-AUY922 is a novel Hsp90 inhibitor
NVP-LAQ824 Catalog#: A-6110
         NVP-LAQ824 is a selective HDAC inhibitor.
NVP-LDE-225 (free base) Catalog#: A-1126F
         NVP-LDE-225 is an Hedgehog inhibitor in clinical trials
NVP-LDE-225(Diphosphate salt) Catalog#: A-1126
         LDE-225 is an Hedgehog inhibitor in clinical trials
NVP-TAE-684 Catalog#: A-1046
         NVP-TAE-684 is a selective NPM-ALK inhibitor with IC50 values between 2 and 10 nM. Treatment of TAE684 resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest in cancer cells.
Obatoclax (GX15-070) Catalog#: A-1022
         Obatoclax (GX15-070) is an inhibit of the Bcl-2.
OICR-9429 Catalog#: A-9063
         OICR-9429 is a cell penetrant, potent and selective antagonist of the interaction of WDR5 (WD repeat domain 5) with peptide regions of MLL and Histone 3 that potently binds to WDR5.
Olmutinib Catalog#: A-6040
         Olmutinib is an inhibitor of mutant EGFR
Omarigliptin(MK-3102) Catalog#: A-1949
         Omarigliptin, also known as MK-3102, is a potent and long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
Omecamtiv mecarbil(CK-1827452) Catalog#: A-1956
         Omecamtiv mecarbil, also known as CK-1827452, is a cardiac specific myosin activator.
ONX-0912 Catalog#: A-1368
         Oprozomib (ONX 0912), a tripeptide epoxyketone, is an ORALLY ACTIVE and irreversible inhibitor of 20S proteasome inhibitor targeting primarily chymotrypsin-like activity.
OPB-31121 Catalog#: A-1104
         OPB-31121 is a Stat3 in clinical trials
OSI-027 Catalog#: A-1065
         OSI-027 is an orally bioavailable mTORC1/C2 kinase inhibitor with anti-tumor activity.
OSI-906(Linsitinib) Catalog#: A-1058
         OSI-906 is a potent, selective orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R).
OSU-03012 Catalog#: A-1209
         OSU-03012 is a PDK1 inhibitor in clinical trials.
OTX-015 Catalog#: A-1349
         OTX-015 is an orally bioavailable and small molecule inhibitor of bromodomain and extra terminal domain (BET) family proteins with EC50 values of 10-19 nM for BRD2, BRD3, and BRD4.
P-1446A-05 Catalog#: A-1074
         P-1446A-05 is a CDK inhibitor in clinical trials.
P-276-00 Catalog#: A-1076
         P-276-00 is a CDK inhibitor in clinical trials
PAC-1 Catalog#: A-6081
         PAC-1 is a selective procaspase 3 inhibitor.
PB-357 Catalog#: A-1708
PCI-24781 Catalog#: A-1081
         PCI-24781 is a HDAC inhibitor in clinical trials
PCI-32765 Catalog#: A-1201
         PCI-32765 is a BTK inhibitor in clinical trials.
PD-0332991 Catalog#: A-1030
         PD-0332991 is an orally available Cdk inhibitor.
PF-00562271 Catalog#: A-1080
         PF-00562271 is a FAK inhibitor in clinical trials
PF-01367338 Catalog#: A-1093
         PF-01367338 is a PARP inhibitor in clinical trials
PF-02341066 Catalog#: A-1031
         PF-02341066 is a potent and selective dual ALK and c-MET inhibitor in clinical trials.
PF-02341066-HCL Catalog#: A-6033
         PF-02341066-HCL is a potent and selective dual ALK and c-MET inhibitor in clinical trials.
PF-03084014 Catalog#: A-1267
         PF-03084014 is a selective gamma secretase (GS) inhibitor with potential antitumor activity.
PF-03715455 Catalog#: A-1412
         PF-03715455 is a p38 inhibitor.
PF-03758309 Catalog#: A-1091
         PF-03758309 is a PAK4 inhibitor in clinical trials
PF-04217903 Catalog#: A-1114
         PF-04217903 is a c-MET inhbitor
PF-04449913 Catalog#: A-1266
         PF-04449913 is an orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity.
PF-04691502 Catalog#: A-1101
         PF-04691502 is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.
PF-04928473 (SNX-2112) Catalog#: A-1710
         PF-04929113 is a potent and selective Hsp90 inhibitor with an IC50 of median 50 nM.
PF-05212384 (PKI-587) Catalog#: A-1071
         PF-05212384 (PKI-587) is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.
PF-06459988 Catalog#: A-6004
         PF-06459988 is an irreversible mutant-selective epidermal growth factor receptor (EGFR) inhibitor
PF-06463922 Catalog#: A-1329
         An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1)
PF-06747775 Catalog#: A-1391
         PF-06747775 is an EGFR(T790M) Inhibitor.
PF-06840003 Catalog#: A-6079
         PF-06840003 is a selective IDO1 inhibitor.
PF-114 Catalog#: A-6089
         PF-114 is a selective BCR-ABL inhibitor.
PF4989216 Catalog#: A-1184
PFI-1 Catalog#: A-1288
         PFI-1 is a BET bromodomain inhibitor that exhibits inhibitory activity at BRD2 and BRD4.
PHA-665752 Catalog#: A-1032
         PHA-665752 is a potent, selective and ATP-competitive inhibitor of c-MET kinase
PHA-848125AC Catalog#: A-1204
         PHA-848125AC is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity.
PKC-412 Catalog#: A-1348
         PKC412 is an orally available staurosporine derivative that inhibits protein kinase C.
PKI-587(PF-05212384) Catalog#: A-1071
         PF-05212384 (PKI-587) is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.
PLX-3397 Catalog#: A-1330
         A capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
PLX-4032(RG7204, RO5185426, Vemurafenib) Catalog#: A-1130
         PLX-4032 is a B-Raf inhibitor
PLX-4720 Catalog#: A-1131
         PLX-4720 is a B-Raf inhibitor.
PLX-7904 Catalog#: A-6064
         PLX-7904 is a selective paradox-breaker RAF inhibitor.
PLX108-01 Catalog#: A-1330
         PLX108-01 (PLX3397) is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.
Poziotinib Catalog#: A-1363
         Poziotinib, also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.
Pp-242 Catalog#: A-1033
         Pp-242 is an mTORC1/C2 inhibitor
PR-171(Carfilzomib) Catalog#: A-1098
         PR-171 is a Proteasome inhibitor in clinical trials
Prasugrel Catalog#: A-9043
         Prasugrel is a platelet inhibitor that reduces the aggregation of platelets by irreversible binding to P2Y12 receptors. Prasugrel interacts in an irreversible manner with the residues Cys97 and Cys175 of the human P2Y12-receptor.
PRI-724 Catalog#: A-1505
         PRI-724 is a potent and selective inhibitor against CBP and beta-catenin binding interaction in cancer stem cells.
PT-2385 Catalog#: A-1510
         PT2385 is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity.
PTC-124 Catalog#: A-1034
PX-866 Catalog#:
         PX-866 is a PI3K inhibitor in clinical trials
Pyridoclax Catalog#: A-1382
         Pyridoclax(MR-29072) is a potent Mcl-1 inhibitor with Kd value of 25 nM.
R-935788 Catalog#: A-1200
         R-935788 is an SYK inhibitor.
Raf-265 (CHIR-265) Catalog#: A-1241
         Raf-265 (CHIR-265), an oral and potent RAF and VEGFR inhibitor in clinical trials
Rapamycin (Sirolimus) Catalog#: A-1035
         Rapamycin is a mammalian target of rapamycin (mTOR C1) inhibitor
RDEA-119 (BAY-869766) Catalog#: A-1036
         RDEA-119 (BAY-869766) is a potent and highly selective MEK Inhibitor
RDEA-427 Catalog#: A-1037
RDEA-436 Catalog#: A-1038
         RDEA-436 is a novel, potent, broadly active MEK inhibitor, with a low EC50 in human serum
RDEA-594 Catalog#: A-1039
RDEA-806 Catalog#: A-1040
Regorafenib (BAY73-4506) Catalog#: A-1112
         Regorafenib (BAY73-4506) is an oral multikinase inhibitor, including B-Raf (IC50, 69 nM), c-KIT (IC 50, 17 nM), VEGFR2 (IC50, 40nM)
Resminostat Catalog#: A-1190
         Resminostat is an HDAC inhibitor in clinicals.
RG-120 Catalog#: A-1934
RG-7388 Catalog#: A-6037
         Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor
RN-486 Catalog#: A-1355
         RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
RO-4924097 Catalog#: A-1260
RO-4929097 Catalog#: A-1263
         RO4929097 is a small molecule Gamma-Secretase inhibitor (IC = 4 nM).
RO-4987655 Catalog#: A-1084
         RO-4987655 is a MEK inhibitor in clinical trials
RO-5126766 Catalog#: A-1085
         RO-5126766 is a dual Raf and MEK inhibitor in clinical trials.
RO-5185426/PLX-4032 Catalog#: A-1130
         RO5185426 (also known as PLX4032) is a B-RAF inhibitor.
RO-5212054/PLX-3603 Catalog#: A-1151
         RO-5212054/PLX-3603 is a B-Raf inhibitor.
RO-5323441 Catalog#: A-1152
Rocaglamide Catalog#: A-1624
         Rocaglamide is an immunosuppressant, and a potent inhibitor of NF-κB activation in T cells, with an almost complete inhibition at 200nM. Suppresses cytokine production (IFN-γ, TNF-α, IL-2 and IL-4) and inhibits NF-AT in peripheral blood T cells at concentrations that do not impair NF-κB and AP-1 activities.
Romidepsin(FK228) Catalog#: A-1340
         Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.
RP-6530 (Tenalisib) Catalog#: A-6066
         RP-6530 (Tenalisib) is a is a potent and selective dual PI3K ?/? inhibitor.
RS 102895 hydrochloride Catalog#: A-1975
         CCR2-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 μM for inhibition of human recombinant CCR2b and CCR1 receptors respectively).
RVX-208 Catalog#: A-1287
         RVX-208 is a small molecule that binds to the bromodomain of BET proteins and prevents them from binding to acetylated lysines on histones, thus influencing gene expression.
RX-3117 Catalog#: A-1364
         RX-3117 is a next generation orally bioavailable nucleoside analog that is activated (phosphorylated) by the enzyme Uridine Cytidine Kinase (UCK) and inhibits both DNA and RNA synthesis which induces apoptotic cell death of tumor cells.
S-49076 Catalog#: A-1281
         S-49076 is a novel, potent MET, FGFR1/2/3 and AXL tyrosine kinase inhibitor.
S-63845 Catalog#: A-6044
         S-63845 is a small molecule MCL1 inhibitor.
S-Ornidazole Catalog#: A-9042
SAHA (Vorinostat) Catalog#: A-1041
         SAHA is an HDAC inhibitor and shows IC 50 of 10 nM (HDAC-1) and 300 nM (rat liver HDAC)
SAR-245408(XL-147) Catalog#: A-1052
         SAR-245409(XL-147) is a PI3k inhibitor in clinical trials.
SAR-245409(XL-765) Catalog#: A-1068
         SAR-245409(XL-765) is a PI3K/mTOR inhibitor in clinical trials;
SAR-260301 Catalog#: A-1311
         PI3K inhibitor
SB-1518 Catalog#: A-1136
         SB-1518 is a JAK2 inhibitor.
SB-216763 Catalog#: A-1042
SB-431542 Catalog#: A-1043
         SB-431542 is a potent and selective inhibitor of transforming growth factor superfamily type I activin receptor-like kinase (ALK) receptors.
SB-939 Catalog#: A-1185
         SB-939 is a novel histone deacetylase (HDAC) inhibitor.
SCH-727965 Catalog#: A-1075
         SCH-727965 is a CDK inhibitor in clinical trials
SCH-772984 Catalog#: A-1333
         SCH772984 is a novel and selective inhibitor of ERK1/2. SCH-772984 effectively inhibits MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models.
SCH-900776 Catalog#: A-1202
         SCH 900776 is a potent and selective CHK1 inhibitor with IC50 of 3 nM, 0.16 and 1.5 μM for CHK1, CDK2 and CHK2, respectively.
Seliciclib Catalog#: A-1282
         Seliciclib (CYC202 or R-roscovitine) is a potent inhibitor of CDK (cyclin dependent kinases) including CDK2/cyclin E, CDK7/cyclin H and CDK9/cyclin T. Seliciclib induces cell apoptosis.
Semagacestat (LY450139) Catalog#: A-1952
         Semagacestat (LY450139) is an blocker of γ-secretase for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM.
SGI-110 Catalog#: A-1294
         SGI-110 is a proprietary dinucleotide pro-drug of decitabine which is a second generation DNA methyltransferase inhibitor.
SGI-1776 Catalog#: A-1102
         SGI-1776 is a PIM kinase inhibitor in clinical trials
SGI-7079 Catalog#: A-1280
         SGI-7079 is an Axl kinase inhibitor.
SGX-523 Catalog#: A-1060
         SGX523 is an orally bioavailable Met inhibitor
Silmitasertib Catalog#: A-1211
         Silmitasertib is an orally bioavailable small-molecule inhibitor of CK2 with potential antineoplastic activity.
Sorafenib (BAY 43-9006) Catalog#: A-1044
SR-13668 Catalog#: A-
         SR13668, an orally active Akt/PKB pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies.
STA-9090 Catalog#: A-1179
         STA-9090 is an HSP-90 inhibitor.
Sutent Catalog#: A-1045
         Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral RTK inhibitor that was approved by the FDA
TAK-441 Catalog#: A-1172
         TAK441 is a Hedgehog inhibitor.
TAK-632 Catalog#: A-1297
         TAK-632 is a potent pan-RAF inhibitor with favorable in vitro activity (BRAF(V600E) IC50, 2.4 nM; BRAF(wt), 8.3 nM; CRAF, 1.4 nM; pMEK (A375) IC50, 12 nM; pMEK (HMVII), 49 nM; V/B ratio.
TAK-659 Catalog#: A-6090
         TAK-659 is a selective SYK inhibitor.
TAK-700 Catalog#: A-1193
         TAK-700 is an oral, selective, non-steroidal androgen synthesis inhibitor of the 17,20 lyase in clinical trials.
TAK-733 Catalog#: A-1225
         TAK-733 is an MEK inhibitor in clinical trials.
TAK-960 Catalog#: A-1264
         TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1
TAK438 Catalog#: A-9061
         TAK438; TAK-438; TAK 438
Talarozole Catalog#: A-1212
         Talarozole is a Cyp26 inhibitor in clinical trials.
Talmapimod(SCIO-469) Catalog#: A-1922
Tamoxifen Citrate Catalog#: A-1916
         Tamoxifen Citrate
Tarceva (Erlotinib, OSI-774) Catalog#: A-1048
         Tarceva is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which was approved for cancer treatment by FDA.
TAS-115 Catalog#: A-1366
TAS-116 Catalog#: A-1924
         TAS-116 is an oral selective HSP90α/β Inhibitor.
TAS-121 Catalog#: A-1390
         TAS-121 is an EGFR tyrosine kinase inhibitor.
Taxotere Catalog#: A-1218
Telatinib (BAY 57-9352) Catalog#: A-1270
         Telatinib (BAY 57-9352) is a potent inhibitor of VEGFR2, VEGFR3, c-Kit and PDGFRβ with IC50 of 6 nM, 4 nM, 1 nM and 15 nM, respectively.
Temozolomide Catalog#: A-1217
         Temozolomide (brand names Temodar and Temodal) is an oral alkylating agent used for the treatment of Grade IV astrocytoma — an aggressive brain tumor, also known as glioblastoma multiforme — as well as for treating melanoma, a form of skin cancer.
TG-101348 Catalog#: A-1140
         TG-101348 is a potent, highly selective JAK2 inhibitor
TG-2 Catalog#: A-1208
         TG-2 is an ERK/Flt3/Jak2 inhibitor in clinical trials.
TGR-1202 (RP-5264) Catalog#: A-1334
         TGR-1202 (RP-5264) is a highly specific, orally available, PI3K delta inhibitor.
TGX-221 Catalog#: A-1050
         TGX-221 is a cell-permeable morpholino-pyrimidinone compound that acts as a reversible, ATP-competitive, selective, and highly potent inhibitor of PI 3-Kb
TKI-258(CHIR-258, Dovitinib) Catalog#: A-1129
         TKI258 is a novel FGFR/PDGFR/VEGFR inhibitor
TL-32711 Catalog#: A-1901
         TL-32711 is a SMAC (second mitochondrial-derived activator of caspases) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity.
TLN-232 Catalog#: A-1326
         TLN-232 is a novel seven amino-acid peptide with potential efficacy in multiple oncology indications that targets pyruvate kinase M2 (M2PK), a protein shown to be over-expressed in a number of different tumour types.
Toremifene citrate salt Catalog#: A-1273
         Toremifene citrate is an oral selective estrogen receptor modulator (SERM). Toremifene citrate is used in advanced (metastatic) breast cancer and being evaluated for prevention of prostate cancer.
Tubacin Catalog#: A-1028
         Tubacin is a selective inhibitor of histone deacetylase 6 (HDAC6), a predominantly cytoplasmic class II histone deacetylase that is involved in many cellular processes, including degradation of misfolded proteins, cell migration, and cell-cell interaction. Tubacin selectively inhibit HDAC6-mediated alpha -tubulin deacetylation.
Tubastatin A Catalog#: A-1159
         Tubastatin A is a potent and selective HDAC6 (histone deacetylase 6) inhibitor.
TX1-85-1 Catalog#: A-6105
         TX1-85-1 is a selective Her3 inhibitor.
USP7-USP47 Catalog#: A-1314
         USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase β
Vandetanib Catalog#: A-9059
         Vandetanib is an orally bioavailable 4-anilinoquinazoline.
Varlitinib(ARRY-543) Catalog#: A-1373
         Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity.
VE-822 Catalog#: A-1613
         VE-822 is an potent ATR inhibitor.
Voruciclib Catalog#: A-1365
         Voruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
VS-4718/PND-1186 Catalog#: A-1356
         VS-4718 is a potent and selective FAK kinase inhibitor that blocks fibronectin-stimulated FAK autophosphorylation at Tyr397 at low nanomolar concentrations.
VS-5584 (SB2343) Catalog#: A-1932
         is a potent and selective dual inhibitor of PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.
VS-6063 Catalog#: A-1707
         MLN9708 is a proteasome inhibitor.
VT-464 Catalog#: A-1327
         VT-464 selectively inhibits the enzymatic activity of the cytochrome P450 (CYP17).
VTP-27999 2,2,2-trifluoroacetate Catalog#: A-1367
         VTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor;
VTX-2337 Catalog#: A-1284
         VTX-2337 is a small molecule Toll-like receptor 8 (TLR8) agonist that stimulates myeloid dendritic cells, monocytes, and enhances NK cell responses.
VX-11e Catalog#: A-1195
         VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK2.
VX-661 Catalog#: A-1309
         VX-661 is CFTR modulator. VX-661 is potentially useful for treatment of cystic fibrosis disease. Cystic fibrosis (CF) is a genetic disease caused by defects in the CF transmembrane regulator (CFTR) gene, which encodes an epithelial chloride channel.
WYE-354 Catalog#: A-1051
         WYE-354 is an mTOR inhibitor
WZ-4002 Catalog#: A-1344
         WZ 4002 is an inhibitor of EGFR phosphorylation in a variety of cancer cell lines including NIH-3T3 and H1975 cells.
WZ-4003 Catalog#: A-1345
         WZ4003 is a first potent and highly specific protein kinase inhibitor of NUAK kinases with IC50 of 20 nM/100 nM for NUAK1/NUAK2; no significant inhibition on 139 other kinases.
X-396 Catalog#: A-6020
         X-396 is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity.
XL-019 Catalog#: A-1137
         XL019 is a potent JAK2 inhibitor (IC50 = 2 nM)
XL-138 Catalog#: A-1173
XL-184(Cabozantinib) Catalog#: A-1089
         XL-184 is a c-Met inhibitor in clinical trials
XL-388 Catalog#: A-1370
         XL 388 is a mTOR inhibitor that inhibits in an ATP-competitive manner. Exhibits >300-fold selectivity for mTOR over PI 3-K and a range of other kinases. Displays antitumor activity in athymic nude mice implanted with tumor xenografts.
XL-499 Catalog#: A-1312
         XL499 is a potent and selective inhibitor of PI3Kδ, a class 1A PI3K isoform expressed primarily in hematopoietic cells and some hematologic malignancies.
Y-39983 Catalog#: A-1210
         Y-39983 is a novel Rock1 inhibitor in clinical trials.
YK-4-279 Catalog#: A-1903
         Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. Inhibits Ewing's sarcoma family tumor (ESFT) cell growth; induces apoptosis.
YM-155 Catalog#: A-1061
         YM-155 is a novel small molecule survivin inhibitor.
ZM-447439 Catalog#: A-1054
ZSTK-474 Catalog#: A-1055
         ZSTK-474 is a PI3Ka/b/g/d inhibitor

*Note: These products are for research purposes only, not for human consumption.